Abstract
Acute myeloid leukemia (AML) is characterized as a heterogeneous disease where the patients are sub grouped according to several classification systems and mutational analyses. Diagnosis of AML is based on identification of the specific myeloid cell initiating the disease, quantification of immature blasts in bone marrow and peripheral blood, as well as detection of mutations and translocations. The heterogeneity of AML is caused by a block in differentiation that may occur in any of the different myeloid cell populations. These undifferentiated cells also harbor an increased proliferation potential that leads to accumulation of immature leukemic cells. The current development of more sensitive and less labor intensive analysis methods has led classification of patients from being a system based on morphology of the leukemic cells to being more sophisticated, detecting translocations and small mutations found in the whole leukemic clone or in a minor subclone. This review aims to describe the most common classification systems of AML, including frequently occurring translocations, mutations and epigenetic alterations, as well as describe traditional and novel methods for diagnosis and analysis of these patients.
Keywords: Acute Myeloid leukemia, sub classification, WHO, mutation, epigenetics, karyotyping, gene array, next generation sequencing.
Current Pharmaceutical Biotechnology
Title:The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Volume: 17 Issue: 1
Author(s): Rakel B. Forthun, Carina Hinrichs, Tara H. Dowling, Øystein Bruserud and Frode Selheim
Affiliation:
Keywords: Acute Myeloid leukemia, sub classification, WHO, mutation, epigenetics, karyotyping, gene array, next generation sequencing.
Abstract: Acute myeloid leukemia (AML) is characterized as a heterogeneous disease where the patients are sub grouped according to several classification systems and mutational analyses. Diagnosis of AML is based on identification of the specific myeloid cell initiating the disease, quantification of immature blasts in bone marrow and peripheral blood, as well as detection of mutations and translocations. The heterogeneity of AML is caused by a block in differentiation that may occur in any of the different myeloid cell populations. These undifferentiated cells also harbor an increased proliferation potential that leads to accumulation of immature leukemic cells. The current development of more sensitive and less labor intensive analysis methods has led classification of patients from being a system based on morphology of the leukemic cells to being more sophisticated, detecting translocations and small mutations found in the whole leukemic clone or in a minor subclone. This review aims to describe the most common classification systems of AML, including frequently occurring translocations, mutations and epigenetic alterations, as well as describe traditional and novel methods for diagnosis and analysis of these patients.
Export Options
About this article
Cite this article as:
Forthun B. Rakel, Hinrichs Carina, Dowling H. Tara, Bruserud Øystein and Selheim Frode, The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia, Current Pharmaceutical Biotechnology 2016; 17 (1) . https://dx.doi.org/10.2174/1389201016666150907113653
DOI https://dx.doi.org/10.2174/1389201016666150907113653 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Asthma, Allergy and Chemokines
Current Drug Targets Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole- Containing Ruthenium Complexes
Mini-Reviews in Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design A Dual Role for Sirtuin 1 in Tumorigenesis
Current Pharmaceutical Design The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Designing a Novel Multi-Epitope Vaccine Against Htlv-1 Related Adult T-cell Leukemia/Lymphoma: An In Silico Approach
Current Proteomics Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Synthesis, Characterization, and Molecular Structure of a Novel Zinc (II) Complex: Assessment of Impact of MDR1Pgp Expression on its Cytotoxic Activity
Medicinal Chemistry 2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 2
Medicinal Chemistry